Exosome Diagnostics Inks RNA-Seq Collaboration With Takeda | GenomeWeb

NEW YORK (GenomeWeb) – Exosome Diagnostics (ExoDx) today announced it has entered into a collaboration with Takeda Pharmaceuticals to develop an exosomal RNA sequencing platform for biomarker discovery.

Under the terms of the agreement, Cambridge, Massachusetts-based ExoDx and Takeda will develop a platform for analyzing gene expression patterns of cancers and other diseases. ExoDx will apply its exosomal RNA isolation technology, RNA sequencing-based biomarker discovery platform, informatics, and signal enhancement technology, among other methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.